Lipid polycation DNA gene delivery system - Targeted Genetics/Elan
Latest Information Update: 14 Apr 2004
At a glance
- Originator Elan Corporation; Targeted Genetics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Apr 2004 Targeted Genetics formally concludes its collaboration with Elan
- 06 Oct 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 24 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Cancer pharmacodynamics section